Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Working Capital Changes (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Other Working Capital Changes for 15 consecutive years, with -$83000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes fell 337.14% to -$83000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$36000.0, a 114.63% decrease, with the full-year FY2024 number at $48000.0, up 536.36% from a year prior.
  • Other Working Capital Changes was -$83000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $33000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.7 million in Q3 2022 to a low of -$295000.0 in Q3 2021.
  • A 5-year average of $90722.2 and a median of $7000.0 in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: surged 680.34% in 2022, then plummeted 337.14% in 2025.
  • NovaBay Pharmaceuticals' Other Working Capital Changes stood at $359000.0 in 2021, then tumbled by 132.59% to -$117000.0 in 2022, then skyrocketed by 282.05% to $213000.0 in 2023, then crashed by 92.96% to $15000.0 in 2024, then tumbled by 653.33% to -$83000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Working Capital Changes are -$83000.0 (Q3 2025), $33000.0 (Q2 2025), and -$1000.0 (Q1 2025).